Coya Therapeutics is a biotech company developing therapies for neurodegenerative diseases. Read why I deem COYA stock as a ...

Coya Therapeutics, Inc. (COYA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Thomas Shrader from BTIG maintained a Buy rating on the stock ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Coya Therapeutics (NASDAQ:COYA) just reported results for the fourth quarter of 2023. Coya Therapeutics reported earnings per ...

In an interview with Pharm Exec Associate Editor Don Tracy, Howard Berman, Chairman, CEO, Coya Therapeutics offers a preview ...

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr.

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics ...

Coya’s Scientific Board Chairman Dr. Stanley Appel and Chief Medical Officer Dr. Fred Grossman to participate in discussion hosted by BTIG Analyst Tom Shrader HOUSTON, March 12, 2024--(BUSINESS ...

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory ...

As of 10:08 AM EDT. Market Open. HOUSTON, April 08, 2024--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to ...